Display options
Cite
Raney RB, Maurer HM, Anderson JR, et al. The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols. Sarcoma. 2001;5(1):9-15doi: 10.1080/13577140120048890.
Raney, R. B., Maurer, H. M., Anderson, J. R., Andrassy, R. J., Donaldson, S. S., Qualman, S. J., Wharam, M. D., Wiener, E. S., & Crist, W. M. (2001). The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols. Sarcoma, 5(1), 9-15. https://doi.org/10.1080/13577140120048890
Raney, R B, et al. "The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols." Sarcoma vol. 5,1 (2001): 9-15. doi: https://doi.org/10.1080/13577140120048890
Raney RB, Maurer HM, Anderson JR, Andrassy RJ, Donaldson SS, Qualman SJ, Wharam MD, Wiener ES, Crist WM. The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols. Sarcoma. 2001;5(1):9-15. doi: 10.1080/13577140120048890. PMID: 18521303; PMCID: PMC2395450.
Copy Download .nbib Format: NLM
Share it on

Sarcoma. 2001;5(1):9-15. doi: 10.1080/13577140120048890.

The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols.

Sarcoma

R B Raney, H M Maurer, J R Anderson, R J Andrassy, S S Donaldson, S J Qualman, M D Wharam, E S Wiener, W M Crist

Affiliations

  1. Department of Clinical Pediatrics UT MD Anderson Cancer Center Houston Texas USA.

PMID: 18521303 PMCID: PMC2395450 DOI: 10.1080/13577140120048890

Abstract

Purpose. To enumerate lessons from studying 4292 patients with rhabdomyosarcoma (RMS) in the Intergroup Rhabdomyosarcoma Study Group (IRSG, 1972-1997).Patients. Untreated patients < 21 years of age at diagnosis received systemic chemotherapy, with or without irradiation (XRT) and/or surgical removal of the tumor.Methods. Pathologic materials and treatment were reviewed to ascertain compliance and to confirm response and relapse status.Results. Survival at 5 years increased from 55 to 71% over the period. Important lessons include the fact that extent of disease at diagnosis affects prognosis. Re-excising an incompletely removed tumor is worthwhile if acceptable form and function can be preserved. The eye, vagina, and bladder can usually be saved. XRT is not necessary for children with localized, completely excised embryonal RMS. Hyperfractionated XRT has thus far not produced superior local control rates compared with conventional, once-daily XRT. Patients with non-metastatic cranial parameningeal sarcoma can usually be cured with localized XRT and systemic chemotherapy, without whole-brain XRT and intrathecal drugs. Adding doxorubicin, cisplatin, etoposide, and ifosfamide has not significantly improved survival of patients with gross residual or metastatic disease beyond that achieved with VAC (vincristine, actinomycin D, cyclophosphamide) and XRT. Most patients with alveolar RMS have a tumor-specific translocation. Mature rhabdomyoblasts after treatment of patients with bladder rhabdomyosarcoma are not necessarily malignant, provided that the tumor has shrunk and malignant cells have disappeared.Discussion. Current IRSG-V protocols, summarized herein, incorporate recommendations for risk-based management. Two new agents, topotecan and irinotecan, are under investigation for patients who have an intermediate or high risk of recurrence.

References

  1. Cancer. 1997 Sep 15;80(6):1165-70 - PubMed
  2. J Pediatr Hematol Oncol. 1997 Nov-Dec;19(6):483-91 - PubMed
  3. World J Surg. 1988 Oct;12(5):676-84 - PubMed
  4. J Clin Oncol. 1997 May;15(5):1831-6 - PubMed
  5. Med Pediatr Oncol. 1990;18(6):466-71 - PubMed
  6. J Pediatr Surg. 1989 Jan;24(1):5-10 - PubMed
  7. Cancer. 1993 Mar 1;71(5):1904-22 - PubMed
  8. J Clin Oncol. 1995 Mar;13(3):610-30 - PubMed
  9. J Pediatr Hematol Oncol. 1995 Nov;17(4):331-7 - PubMed
  10. Science. 1990 Nov 30;250(4985):1233-8 - PubMed
  11. J Clin Oncol. 2001 Jan 1;19(1):213-9 - PubMed
  12. J Clin Oncol. 1999 Nov;17(11):3468-75 - PubMed
  13. J Clin Oncol. 1993 Feb;11(2):262-70 - PubMed
  14. J Clin Oncol. 1990 Mar;8(3):443-52 - PubMed
  15. Cancer. 1988 Jan 15;61(2):209-20 - PubMed
  16. Am J Epidemiol. 1992 Jan 15;135(2):190-9 - PubMed
  17. J Clin Oncol. 1988 Jan;6(1):67-75 - PubMed
  18. J Pediatr Surg. 2000 Jun;35(6):961-4 - PubMed
  19. Med Pediatr Oncol. 1994;23(2):99-106 - PubMed
  20. J Clin Oncol. 1997 Jan;15(1):69-75 - PubMed
  21. J Clin Oncol. 1996 Mar;14(3):886-900 - PubMed
  22. J Pediatr Hematol Oncol. 1997 Mar-Apr;19(2):124-9 - PubMed

Publication Types